ISR has received FDA 510(k) clearanceC4 Imaging Announces Sirius Positive Signal MRI Marker Given FDA 510(k) Clearance for Use with Isoray’s Cesium-131 Brachytherapy Seeds to Treat Prostate Cancer
ISR has received FDA 510(k) clearance for the use of C4 Imaging’s Sirius® positive-signal MRI (Magnetic Resonance Imaging) Markers with Isoray’s Cesium-131, brachytherapy seeds.
Sirius MRI Markers will enable Isoray’s customers to fully utilize the benefits of MRI seed localization.
Brachytherapy, or internal radiation therapy, is a leading, cost-effective option for the treatment of prostate cancer. Isoray is the world’s only producer of Cesium-131, commercially known as Cesium Blu™, brachytherapy seeds. Cesium-131 is a radioactive isotope that delivers a minimally invasive and highly targeted treatment to the site of the cancer preserving healthy tissue and organs. Patients benefit from the rapid resolution of their side effects allowing them to return to their normal lives quickly.
finance.yahoo.com
Stockpicks
“Strong Buy” Penny Stock That Could Deliver Massive Returnis engaged in the development of gene therapies for rare, frequently terminal, diseases, including neurometabolic disorders, primary immune deficiencies, and blood disorders. The gene therapy approach uses blood stem cells to deliver corrected genetic information directly into the patient’s body.
Orchard’s pipeline demonstrates the diversity of disorders amenable to gene therapy – the company has no less than 12 drug candidates in development. Among these candidates, Libmeldy (OTL-200) stands out.
Libmeldy is in commercialization stages as a treatment for MLD (metachromatic leukodystrophy), a rare, mutation-based genetic disorder of the nervous system, received its approval for medical use in the EU in December 2020.
“We look forward to the company’s commercial execution in the EU and an eventual 2022 approval in the US. Last month ORTX received IND clearance from the FDA for the program paving the way for discussions with the US regulators to decide a suitable path forward toward a BLA filing.”
with possibly two gene therapies approved in the next 12-18 months and a pivotal study beginning in a third (MPS-I), we think ORTX shares are undervalued at these levels," the analyst concluded.
Wedbush analyst David Nierengarten rates ORTX as Outperform (i.e. Buy), and his $15 price target indicates a potential for 241% growth in the year ahead.
Only Buy ratings, 3, in fact, have been issued in the last three months. Therefore, ORTX gets a Strong Buy consensus rating. At $15, the average price target indicates shares could appreciate by 241% in the year ahead.
finance.yahoo.com
Social Capital Hedosophia Holdings Corp $IPOC - investment id💡 Clover Health Merger Approved By Shareholders
m.benzinga.com
--
This idea is based on my technical analysis only.
Do your research and trade on your own risk!
Is Facebook losing friends?Facebook has been a holding in the portfolio since late November but has been a slow moving loser. The low end of the weekly range (rectangle low 264) was tested today but price responded well. I have been looking for all-time highs but its recent performance has given me doubts. For now we just sit and wait. The company is definitely not getting the love it once did but that can change at anytime. Todays low will be the line in the sand. Below todays low we will cut the position and re-evaluate
$ZOM entry PT .40 PT .90 and higherZomedica Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies. The company is also developing ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. It has a collaboration agreement with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
Hoping Li can regain its spark #stocksLi is current reversal play in the portfolio with a stop below 26. After a brief exit to the downside from the near term range (rectangle box), the stock has reversed back up into the range. I am playing for a further breakout above 35. The stock is very volatile so I am giving it room. Todays down move and anywhere between here and the 27 area are still buying opportunities as long as the reversal structure stays intact and we can get some positive rate of change.
Stay in autopilot or hit the brakes?Tesla's run has been nothing but extraordinary but as always in trading the question is what is next. The two trendlines are just the 3 and 4 standard deviation regression lines from the range breakout from November. If you are in the stock you could take some profits below those lines but that does not mean to short the stock. The near term range low zone is 655 to 614. Above those levels the trend is still up but if tesla closes below that area with any significance then the trend would be more bearish. This expansion breakout out of the longer term range has been strong and the stock may feel "overvalued" but don't trade on feelings. For now lets wait to see how price reacts to the regression lines and then the near term range low before we make any decisions
Ranges- are identified by the white boxes. Will always be classified by a swing high and low on either a monthly or weekly basis
Game Plan #stocksAirbnb has a near term range from about 151 to 143. That area is resistance for now but if we can get a close above 151 there could be larger reversal play to the upside. For now we remain patient. So far there has been no trend. The next area of interest would be the lows near 121.
The9 to Start the Cryptocurrencies BusinessThe9 Signed a Legally Binding Cooperation and Investment Term Sheet with Cryptocurrencies Mining Investors Led by Jianping Kong to Start the Cryptocurrencies Business
The9 has begun to deploy its blockchain and cryptocurrencies business strategy. This time, we are cooperating with investors including Mr. Jianping Kong. They have rich experience and resources in the field of cryptocurrencies mining machine manufacturing and cryptocurrencies mining operation and should be able to assist The9 to launch our cryptocurrencies mining operation. Our goal is to build up cryptocurrencies mining machines for The9 that will contribute 8% to 10% of the global hash rate of Bitcoin, 10% of the global hash rate of Ethereum and 10% of the global hash rate of Grin and become one of the world's largest cryptocurrencies mining companies in terms of hash rate. This will also speed up our other cryptocurrency related businesses. It has been 12 years since the birth of Bitcoin.
Pursuant to the Term Sheet, The9 will issue Class A ordinary shares and warrants to the Investors. The9 is expected to receive proceeds from the transactions contemplated under the Term Sheet in accordance with certain pre-agreed conditions, if realized. The Investors are expected to utilize their cryptocurrencies mining industry resources to assist The9 for its development of cryptocurrencies mining business. The9 will set up a new wholly owned subsidiary NBTC Limited to operate its blockchain and cryptocurrencies business.
The9 will issue 8,108,100 Class A ordinary shares (equivalent to 270,270 ADSs) at US$0.1233 per Class A ordinary share (equivalent to US$3.7 per ADS) and 207,891,900 warrants, each warrant representing the right to purchase one Class A Ordinary share (equivalent to 6,929,730 ADSs assuming full exercise of warrants) to the Investors.
The warrants will be divided into four equal tranches:
- The exercise price of three tranches of warrants is US$0.1233 per Class A ordinary share (equivalent to US$3.7 per ADS)
- The exercise price of the other tranche of warrants is US$0.2667 per Class A ordinary share (equivalent to US$8 per ADS).
Each tranche of the warrants is subject to its vesting conditions including market capitalization of The9 reaching US$100 million, US$300 million, US$500 million and US$1 billion within the timeframes of 6 months, 12 months, 24 months and 36 months, respectively. If the Investors exercise all of the warrants, The9 is expected to raise an aggregate consideration of approximately US$34 million in this transaction from the Class A ordinary shares issuance consideration and warrants exercise. The9 has the right to decide whether the Investors shall make payments in the form of U.S. dollars or cryptocurrencies (including Bitcoin) in the definitive agreement.
finance.yahoo.com
Line in the sand #stocksDJIA is testing its recent weekly low. This is an important level because a close below 29956 could mean a further move down into the breakout rectangle support zone from 29530 - 28328. For now the trend is still up despite the heavy selling today but lets keep an eye out for how the market closes today. Volatility is up but not near the highs of December and it seems to be moving much more then the overall market. We don't want to panic sell into the lows but we should remain cautious.
$PATI Patriot Transportation Holding IncSpecial Ex Dividends have been paid out and its left a juicy money gap to fill. $PATI is oversold on the daily because of this drop. Remember....What comes down, will bounce back up! Enjoy the profit ride. #pati
The $115+ NNOX Target + Patterns$NNOX is one of those volatile stocks that took the world by storm. If you don't like volatility, it is likely best to stay away from biotech or healthcare. That said, there are alot of expected catalysts. $NNOX have been heavily shortened, and it is in the opinion of many that lots of market manipulation has been and is going on. The short interest is low and the borrow rate is high. Currently as I see it, the pattern is still incrementally upwards. Nanox has the catalyst of factory announcements, FDA approvals for both single and multisource, plus the commencement of "device leasing". Currently with 4 catalyst, three of them that are expected to be big, a target of $115 seems reasonable. Support levels should be picking up soon, and unless one wants to flip for few cents or dollars per share as profit, this currently seems much better suited for a long term position. That said, I am long. Everything I say is on an opinion based basis. Please do your own due diligence and proceed with caution. Opinions mentioned here aren't meant to warrant solicited financial advice.
ZKIN Buy the uptrend setup.ZKIN - Intraday - We look to buy at 2.33 (stop at 2.17)
20 4-hour EMA is at 2.37
The price continues to find uptrend on 20 EMA.
We look to buy dips.
Dip buying offers good risk reward.
Daily signals are bullish.
The bias is to break to the upside.
Trend line support is located at $2.33.
Price has formed a bullish ascending triangle formation.
Our profit targets will be 2.95 and 3.19
Resistance: 3.00 / 3.20 / 3.40
Support: 2.80 / 2.60 / 2.40
XpresSpa Group Inc $XSPA - Investment idea 💡 This is not just a penny stock, but also a good investment for long term, however if you're not planning to hold for long term, then I suggest you to take profits on each target level.
--
Do your research and trade on your own risk!
Almaden Minerals $AAU - Penny Stock Idea 💡 🚀This idea is based on my technical analysis only.
Do your research and trade on your own risk!
$BANT PT 2-4 SupernovaBantec, Inc., an unmanned aerial vehicles (UAV) and related services and technology company, focuses on the distribution and integration of advanced low altitude UAV systems, services, and products worldwide. It also provides product procurement, distribution, and logistics services. In addition, the company offers drones; drone accessories, training, and services; counter-drone technology; certificates of authorization; and Waivers, as well as drone pilot services. Further, it supplies spare and replacement parts to various federal government agencies, military prime contractors, and commercial customers. Additionally, the company operates an online store for Covid-19 sanitizing products and robots. Bantec, Inc. is headquartered in Little Falls, New Jersey.
Right on the edgeSedg has had a great run and has been recently testing the top end of the range. Range highs and lows are always potential phase transition points. We will either see a reversal back into the range or a further breakout. Given the stocks recent big move and the overall sentiment in the solar space I am less confident about the breakout but I am still on the sidelines for now waiting for a more definitive close in either direction.
Plug Power $PLUG - investment idea 💡 Beautiful discount 👌
This idea is based on my technical analysis only.
Do your research and trade on your own risk!
LOAC Announces Signing of Definitive Merger AgreementLongevity Acquisition Corporation Announces Signing of Definitive Merger Agreement
4D pharma's Live Biotherapeutic Products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has six clinical programs
At the effective time of the merger, each of LOAC's ordinary shares issued and outstanding prior to the effective time of the merger will be automatically converted into the right to receive certain per share merger consideration, and each warrant to purchase LOAC's ordinary shares and right to receive LOAC's ordinary shares that is outstanding immediately prior to the effective time of the merger will be assumed by 4D pharma and automatically converted into a warrant to purchase ordinary shares of 4D pharma and a right to receive ordinary shares of 4D pharma, payable in 4D pharma ADSs, respectively.
www.prnewswire.com
Are all-time highs in the cart?The range trade from November 13 has been like watching paint dry until today. You can see the overall decrease in the net volume amplitudes- a sign of little movement in either direction. With todays big move we now sit a little above the mid point of the range but where is amzn heading next? As long as the broader market uptrend remains intact amzn could be heading back toward all time highs. The reference point to watch is Fridays low 3169. If that holds the trade is still on and the highs of the range is our initial target
Can the recent breakout hold?Wabtec has broken out of the 5 month range and is hovering near the top end of the breakout zone. The question is whether we will see a continuation of the upward trend or a reversal back into range. Given the strength in the overall market it would be safer to bet on the continuation of the breakout. As long as price holds above the 70 area the uptrend is still in tact. Below 70 there might be a further correction back into the range
AST & Science LLC to Become Public Company via NPA spac companyAST & Science LLC to Become Public Company Through Combination with New Providence Acquisition Corp. (NASDAQ: NPA, NPAUU and NPAWW)
- AST & Science LLC ("AST SpaceMobile") is building the first and only space-based cellular broadband network accessible directly by standard mobile phones.
- Combined company to have an estimated post-transaction enterprise value of $1.4 billion and will become listed on the NASDAQ under the ticker symbol "ASTS" following expected transaction close in the first quarter of 2021.
Expected to have an equity value of approximately $1.8 billion at closing, or 1.4 times calendar year 2024's estimated EBITDA of approximately $1 billion. The company will have no debt on the balance sheet at closing.
- Transaction to provide up to $462 million in gross proceeds, comprised of New Providence Acquisition Corp.'s $232 million of cash held in trust (assuming no redemptions) and a $230 million fully committed common stock PIPE at $10.00 per share, including investments from Rakuten, Vodafone, American Tower, UBS O'Connor and a broad base of financial institutions
- AST SpaceMobile LLC shareholders Vodafone, Rakuten, American Tower, and Cisneros will increase their equity holding through participation in the PIPE financing in support of AST SpaceMobile's transition into the publicly listed company.
Backed by an extensive IP and patent portfolio, AST SpaceMobile will uniquely address the $1 trillion global mobile wireless services market
finance.yahoo.com
Ford Motors $F - investment idea 💡 New opportunity is coming soon wait for it around 8.5
This idea is based on my technical analysis only.
Do your research and trade on your own risk!
